Dry powder tobramycin    (DrugBank: Tobramycin)

1 disease
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis5

299. Cystic fibrosis    [ 1,592 clinical trials,   1,539 drugs,   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways]
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03485456
(ClinicalTrials.gov)
May 29, 201926/3/2018DPI-Tobra-Kind Cyclops® in Children With Cystic FibrosisPharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin Via the Cyclops® in Children With Cystic FibrosisCystic FibrosisDrug: TobramycinUniversity Medical Center GroningenNULLRecruiting6 Years18 YearsAll10Phase 1;Phase 2Netherlands
2NCT03341741
(ClinicalTrials.gov)
March 11, 20143/11/2017Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF PatientsCombined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF PatientsCystic Fibrosis With Pulmonary ManifestationsDrug: Tobramycin Powder;Drug: ColistinUniversity Hospital TuebingenNULLCompleted12 YearsN/AAll26Phase 3NULL
3NCT02035488
(ClinicalTrials.gov)
October 201327/12/2013Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis BronchiectasisPharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis BronchiectasisBronchiectasisDrug: TobramycinUniversity Medical Centre GroningenNULLCompleted18 YearsN/ABoth8Phase 1;Phase 2Netherlands
4EUCTR2012-004437-16-NL
(EUCTR)
15/05/201319/03/2013Pharmacokinetic evaluation and local tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasisPharmacokinetic evaluation and tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis - Tobra-02 BronchiectasisLung infections;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: Dry powder tobramycin
Product Code: J01GB01
INN or Proposed INN: Tobramycin dry powder
Other descriptive name: TOBRAMYCIN
University Medical Center GroningenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
5EUCTR2016-005014-21-NL
(EUCTR)
31/10/2020Pharmacokinetic evaluation and tolerability of dry powder tobramycin viathe Cyclops® in children with cystic fibrosisPharmacokinetic evaluation and tolerability of dry powder tobramycin via the Cyclops® in children with cystic fibrosis - DPI-tobra-child Cystic FibrosisLung infections;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: Dry powder tobramycin
Product Code: J01GB01
INN or Proposed INN: TOBRAMYCIN
Other descriptive name: TOBRAMYCIN
Product Name: Nebulization tobramycin
INN or Proposed INN: TOBRAMYCIN
Other descriptive name: TOBRAMYCIN
University Medical Center GroningenNULLNAFemale: yes
Male: yes
10Phase 2Netherlands